Sanofi (NASDAQ:SNY) Shares Sold by National Bank of Canada FI

National Bank of Canada FI trimmed its holdings in Sanofi (NASDAQ:SNY - Free Report) by 16.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 297,845 shares of the company's stock after selling 60,595 shares during the period. National Bank of Canada FI's holdings in Sanofi were worth $17,165,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in SNY. GFS Advisors LLC raised its holdings in shares of Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company's stock worth $738,000 after acquiring an additional 11,655 shares during the last quarter. Legacy Capital Wealth Partners LLC raised its stake in Sanofi by 114.2% in the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company's stock valued at $1,399,000 after purchasing an additional 12,942 shares during the last quarter. Icon Wealth Advisors LLC lifted its holdings in Sanofi by 7,954.4% in the 3rd quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company's stock valued at $16,873,000 after purchasing an additional 289,144 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Sanofi by 15.2% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company's stock worth $5,673,000 after buying an additional 15,439 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Sanofi in the third quarter valued at approximately $8,728,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Down 0.7 %

Shares of SNY traded down $0.35 during mid-day trading on Tuesday, reaching $48.08. The company had a trading volume of 2,017,160 shares, compared to its average volume of 2,058,971. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The firm has a fifty day simple moving average of $51.71 and a 200-day simple moving average of $52.12. The stock has a market cap of $122.02 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.55 earnings per share. On average, sell-side analysts anticipate that Sanofi will post 4.27 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on SNY shares. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a report on Friday. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.